Company
(Symbol)^#*

Partner
(Country)

Amt. (M)

Triggering
Event

Details (Date)

Amira
Pharmaceuticals
Inc.*

F. Hoffmann-
La Roche Ltd.
(Switzerland)

ND

Milestone
payment

Triggered by Amira's identification of a series of drug candidates against a target from their collaboration on inflammatory diseases (11/1)

Maxygen Inc.
(MAXY)

F. Hoffmann- La Roche Ltd. (Switzerland)

$2

Milestone payment

Triggered by Roche's initiation of a Phase Ia trial of Maxy- alpha, a next-generation interfer- on alpha for treating hepatitis C virus infection (11/7)

Medarex Inc.
(MEDX)

Amgen Inc.

ND

Milestone
payment

Triggered by Amgen's advancement into clinical trials of an antibody developed using Medarex's UltiMAb technology (11/13)

Memory
Pharmaceuticals
Corp. (MEMY)

Stanley Medical Research Institute

$0.96

Milestone payment

Triggered by certain progress made in the ongoing Phase IIa trial of MEM 1003 in patients with acute mania in bipolar disorder (11/20)

Neose
Technologies
Inc. (NTEC)

Novo Nordisk A/S (Denmark)

ND

Milestone payment

Triggered by undisclosed progress in their 2003 deal to use Neose's GlycoPEGylation technology to develop a next- generation version of Factor VIIa (11/27)

Neurogen
Corp. (NRGN)

Merck & Co. Inc.

$3

Milestone payment

Triggered by Merck's initiation of a Phase II trial of MK- 295(NGD-8243) for treating post-operative dental pain; their work targets the VR1 receptor (11/1)

NovaDel
Pharma Inc.
(AMEX:NVD)

Par Pharmaceutical Cos. Inc.

ND

Milestone payment

Triggered by FDA approval of NitroMist (nitro- glycerin lingual aerosol) for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease (11/3)

Pharmasset
Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

$7.5

Milestone payment

Triggered by Pharmasset's completion of certain manufacturing- related activities in their deal to develop nucleoside polymerase inhibitors against hepatitis C virus (11/9)

Spectrum
Pharmaceuticals
Inc. (SPPI)

Par Pharmaceutical Cos. Inc.

$5

Milestone payment

Triggered by the FDA's tentative approval of sumatriptan injection for treating migraine (11/13)

Vernalis plc
(UK; VNLS)

Novartis AG
(Switzerland)

$1.5

Milestone payment

Triggered by Novartis' selection of a second compound as a preclinical development candidate in their oncology collaboration focused on Hsp90 (11/20)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

AMEX = American Stock Exchange.